Amgen Inc.

AMGN

US0311621009

Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows: - drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.; - other (5.8%): primarily royalties. The United States account for 70.3% of net sales.

Sector

Pharmaceuticals

Calendar

06/06/2024 - Jefferies Global Healthcare Conference

Related indices

Dow Jones Industrial , S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for Amgen Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

307.4 USD

Average target price

316.3 USD

Spread / Average Target

+2.90%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
AMGEN INC.	+7.67%	165B
ELI LILLY AND COMPANY	+42.62%	750B
NOVO NORDISK A/S	+34.11%	606B
JOHNSON & JOHNSON	-6.28%	356B
MERCK & CO., INC.	+18.80%	326B
ABBVIE INC.	+6.32%	286B
ASTRAZENECA PLC	+18.08%	246B
ROCHE HOLDING AG	-3.44%	213B
NOVARTIS AG	+11.35%	213B
PFIZER, INC.	+2.33%	167B

Other Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 17:05:41 05/06/2024 BST			5-day change	1st Jan Change
309.8 ^USD	+0.78%		+4.64%	+7.67%

04:23pm	Amgen Says Phase 3 Trial of Potential Autoimmune Disease Treatment Meets Endpoints	MT
03:44pm	Amgen's Uplizna Hits Phase 3 Endpoints in IgG4-RD	DJ

Amgen Says Phase 3 Trial of Potential Autoimmune Disease Treatment Meets Endpoints	03:23pm	MT
Amgen's Uplizna Hits Phase 3 Endpoints in IgG4-RD	02:44pm	DJ
Amgen's drug meets main goal in late-stage study for rare disease	02:30pm	RE
Amgen Announces Positive Results for Phase 3 Registrational Trial Evaluating Uplizna® (Inebilizumab-Cdon) for Treatment of Immunoglobulin G4-Related Disease (Igg4-Rd)	02:00pm	CI
US FDA approves Amgen's biosimilar to AstraZeneca's rare blood disorder treatment	05-28	RE
Amgen's Rare-Disease Treatment Biosimilar Bkemv Gets FDA Approval	05-28	DJ
Weight-loss drug forecasts jump to $150 billion as supply grows	05-28	RE
Sandoz: Marketing authorization for Wyost and Jubbonti in the EU	05-22	CF
Roche Gets US FDA Breakthrough Designation For Lipoprotein(a) Test	05-22	MT
Transcript : Amgen Inc. - Special Call	05-20
HSBC Adjusts Price Target on Amgen to $356 From $322	05-20	MT
Amgen and AstraZeneca's Lung Disease Drug Study Reports Mixed Results	05-20	MT
Amgen Announces the Results of the Phase 2a COURSE Trial Evaluating Tezspire® (Tezepelumab-Ekko) in People with Moderate to Very Severe Chronic Obstructive Pulmonary Disease	05-19	CI
US FDA approves Amgen drug for small cell lung cancer	05-17	RE
FDA Approves Amgen's IMDELLTRA?? (Tarlatamab-Llle) for the Treatment of Adult Patients with Extensive-Stage Small Cell Lung Cancer	05-16	CI
Amgen Gets FDA Approval for Small-Cell Lung-Cancer Treatment	05-16	DJ
Amgen's Imdelltra Gets US FDA Accelerated Approval for Drug to Treat Extensive Stage Small Cell Lung Cancer	05-16	MT
US FDA approves Amgen drug for small cell lung cancer, Bloomberg News reports	05-16	RE
Transcript : Amgen Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 09:20 AM	05-14
Redburn Adjusts Price Target on Amgen to $170 From $180, Keeps Sell Rating	05-13	MT
ANALYST RECOMMENDATIONS : UBER, Luluemon, Airbnb, Progressive...	05-09
Redburn Atlantic Adjusts Price Target on Amgen to $180 From $170	05-09	MT
Mizuho Securities Raises Amgen's Price Target to $235 From $223	05-08	MT
North American Morning Briefing : Stock Futures -2-	05-06	DJ
Health Care Climbs as Amgen Surges on Obesity-Drug Plans - Health Care Roundup	05-03	DJ